Edoceo Shareholders Excited by News about A-Detect™ CE Approved COVID-19 Testing Kits

Boulder, CO: Edoceo Devices announces the signing of a worldwide strategic and preferred distribution agreement for a simple, rapid, and affordable Saliva based COVID-19 antigen test, A-Detect™, that provides results in 17 minutes or less.   

The test is approved for sale now in the European Union consisting of 28 countries and another 5 countries that accept the European Union CE Mark.  

“We believe that over 213 million COVID-19 tests of all types have been carried out so far in 2020 in Europe, and the United States is currently testing approximately 1.5 to 2.2 million people per day for COVID-19,” says Rod Reum, CEO Edoceo Devices. “The Edmond J. Safra Center for Ethics at Harvard University published a report in April 2020 that suggests that up to 20 million tests per day are needed to help fully remobilize the economy. We have not come close to that and most areas still face lock downs and severe restrictions on businesses. We are delighted to have secured a substantial quantity of rapid antigen testing units with the potential to help people and business get back to a more normal life as soon as possible.”  

The potential additional revenue from commercializing A-Detect can also help speed development of the new generation Edoceo V-Detect™ and B-Detect™ testing devices and boost the rate of potential returns for early investors in our company.

Features and benefits of the A-Detect Rapid Saliva Coronavirus Test Kit include:

• The test provides results on the spot for point-of-need applications 
• The test is non-intrusive, saliva based with no mixing or mailing of sample 
• It is CE Certified allowing for immediate distribution in 33 Countries 
• It is easy to use with minimal contact for medically trained personnel